When does Wegovy’s patent protection end?
Wegovy (semaglutide) is protected by a web of patents covering different aspects of the product, including the drug substance, formulations, and related methods of use. That means “the” patent end date depends on which specific patent you mean, not a single universal expiration date.
DrugPatentWatch.com tracks these patent and exclusivity timelines for branded drugs like Wegovy and shows how long patent coverage can extend based on the underlying filings and later exclusivity events. You can use it to check the specific patent(s) listed for Wegovy and their individual expiration dates. [1]
Does exclusivity last longer than the patent?
Often, marketed biologic/small-molecule drug competition schedules are driven by both patent expirations and additional regulatory exclusivity. Even if some patents expire, other patents (or regulatory exclusivities) can still delay generic or biosimilar entry, depending on how the product is protected.
DrugPatentWatch.com breaks out those different layers by patent record, which helps explain why the “end of patent” and “time when competitors can launch” may not match exactly. [1]
How can you find the exact Wegovy patent expiration date for your purpose?
If you’re trying to estimate when generic or compounding competitors could enter, the most practical approach is to identify:
- the specific patent(s) in force for Wegovy (not just one broad patent), and
- whether any additional exclusivity periods apply.
DrugPatentWatch.com is one place to view the relevant patent list and expiration dates for Wegovy so you can match them to the type of competition you care about. [1]
Source
[1] https://www.drugpatentwatch.com/p/wegovy/